Aaron E. Miller - Articles and news items

Aubagio® Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study

Industry news / 3 October 2013 / Sanofi

Data presented at ECTRIMS highlight potential of early intervention with Aubagio to delay second clinical attack and reduce MRI lesion burden…

Genzyme logo

Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study

Industry news, News / 25 April 2013 / Sanofi

Genzyme announced positive top-line results from the TOPIC trial for AUBAGIO…

Gene to drugs: can expression be the key to new discoveries?

Genomics, Issue 1 2013 / 25 February 2013 / Esther P. Black, College of Pharmacy and Markey Cancer Center, University of Kentucky

Cancer treatment faces a conundrum: a growing lack of therapeutics with lasting effects. The low hanging fruit of the medicinal chemistry orchard seems to have been picked, and modification of existing anti-cancer therapeutics has produced only incremental rewards[1]. Thus, both pharmaceutical companies and academic researchers are left searching for new strategies that will yield novel, long-lasting therapies and methods to rationally utilise existing therapies, alone and in combination, to individualise treatment regimens. The search for novel anti-cancer therapeutics or novel uses for existing drugs can benefit from the maturity of pharmacogenomics to extract genomic information for identification of new targets and therapeutic strategies.

Genzyme logo

FDA approves Genzyme’s AUBAGIO®

Industry news, News / 12 September 2012 / Sanofi

AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing Multiple Sclerosis…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...